Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 84
- Registration Number
- NCT04910126
- Locations
- 🇨🇳
Union Hospital，Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-05-28
- Target Recruit Count
- 420
- Registration Number
- NCT04907344
- Locations
- 🇨🇳
Breast Cancer Department I, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
🇨🇳Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Qian Chu
- Target Recruit Count
- 28
- Registration Number
- NCT04888429
- Locations
- 🇨🇳
The first Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 37
- Registration Number
- NCT04888806
SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 88
- Registration Number
- NCT04878107
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT04861467
- Locations
- 🇨🇳
Cancer hospital, Chineses Academy of Medical Sciences, Beijing, China
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-04-20
- Target Recruit Count
- 15
- Registration Number
- NCT04850040
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
- Conditions
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT04830267
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China
🇨🇳The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 60
- Registration Number
- NCT04805736
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
- Conditions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 1000
- Registration Number
- NCT04793139
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.